Overview

Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV With Hemophilia.

Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of OP-724 in liver cirrhosis patients caused by HIV/HCV co-infection with hemophilia.
Phase:
Phase 1
Details
Lead Sponsor:
Kiminori Kimura, MD
Collaborators:
Japan Agency for Medical Research and Development
Ohara Pharmaceutical Co., Ltd.